Dr. McFarland is an active member of the Center for Translational Research in Neurodegenerative Disease (CTRND) which aims to bring the bench closer to the bedside. His research focuses on understanding the pathological mechanisms of Parkinson disease and related disorders, and in particular the role of alpha-synuclein in cell toxicity and neurodegeneration. His current studies utilize both cellular and preclinical models to study genes and molecules that may affect brain pathology. A primary goal of his research is to identify and to develop potential novel therapeutics for Parkinson disease and related disorders. His research extends also to the clinic where he is actively involved in multiple clinical trials for atypical Parkinson disorders and Huntington disease.
A35-009 (ORION) is a Phase 2b/3 trial to evaluate the efficacy and safety of AMX0035 in participants with Progressive Supranuclear Palsy (PSP), consisting of randomized, double blind placebo controlled phases, followed by an optional open-label鈥�
This is a Phase 2, double-blind, parallel-group, placebo-controlled study to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of multiple doses of ONO-2808 in patients with MSA. This is the first study of ONO-2808 in鈥�
92 publications
2022
Frontiers in cellular neuroscience
鈥�2021
Movement disorders : official journal of the Movement Disorder Society
鈥�2021
Frontiers in neurology
鈥�2021
Acta neuropathologica communications
鈥�2021
Journal of Parkinson's disease
鈥�